Breast Cancer Trial, Recruiting NCT06345534 Sponsor: University Hospital, Ghent Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06345534
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with breast cancer confirmed by a tissue sample analysis
  • People aged 18 years or older
  • People of any gender (male or female)
  • People who have had surgery to remove breast cancer, either by removing the whole breast or by removing only the affected area, with the goal of curing the cancer
  • People for whom a team of medical specialists has decided that radiation therapy after surgery is needed

Who may not be able to join:

  • People whose cancer has spread to other parts of the body
  • People for whom radiation therapy before surgery has been planned
  • People for whom radiation therapy to only part of the breast has been planned
  • People whose surgery showed that cancer cells were found right at the edge of the removed tissue, meaning the surgeon could not get a clear margin around the tumour
  • People who need radiation therapy targeted specifically at a lymph node or lymph nodes
  • People who have previously had radiation therapy to the chest area or the armpit area on the same side, including previous radiation to the other breast or chest wall
  • People who need radiation therapy on both sides of the chest
  • People who have had breast reconstruction surgery or have a tissue expander in place
  • People who are considered unlikely to follow the study requirements, such as those unable or unwilling to complete questionnaires at various points throughout the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Liv Veldeman, MD, PhD, UZ Ghent

Phone: 09 332 30 15

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Ghent
Registry
ClinicalTrials.gov
Start date
30 May 2024
Est. completion
31 December 2033

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Early side effects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov